CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene

CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...
PCMag Australia on MSN

Wow-Worthy Builds Only: The 12 Top PC Cases We Saw at CES 2026

Artsy limited editions, unusual open-frame designs, retro throwbacks, and bold new ideas made this a standout year for the PC ...
NFL Spin Zone on MSN

2026 NFL mock draft: Full two-round mock draft predictions

The latest 2026 NFL mock draft predictions take a look at the first two rounds with quarterbacks at a premium, and teams ...
Tracks Magazine

The midlength revolution and why it’s here to stay

Shortboard purists will say that mid lengths are for out-of-shape or delusional surfers who take all the set waves and ...

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward "AI That Ships," Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Black Book's preview indicates that capital allocators are entering JPM Week 2026 with a clear bias toward deployable, integration-ready healthcare AI, measurable administrative cost takeout, and ...

Investor Lessons From 2025 For 2026

The S&P 500 ended the first week of 2026 with a gain of roughly 1.1%, marking a positive start to the year. Read more here.

Black Book Research: Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward "AI That Ships," Admin Cost Takeout, and Differentiated Metabolic Assets With Special ...

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes) and renewed appetite for carve-outs, milestone bridges, and ...